• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Frontiers retracts 2022 fisetin study over image integrity concerns

by
November 12, 2026
in Health
Reading Time: 3 mins read
0
Frontiers retracts 2022 fisetin study over image integrity concerns

Frontiers retracts 2022 fisetin study over image integrity concerns

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Frontiers in Pharmacology has formally retracted a 2022 research article that claimed fisetin attenuated oxidative stress-induced cellular damage in ARPE-19 human retinal pigment epithelial cells. The retraction notice, published on 11 November 2026, states that the data and conclusions of the original study have been deemed unreliable following an investigation into the integrity of the published figures. The original article, titled “Fisetin Attenuated Oxidative Stress-Induced Cellular Damage in ARPE-19 Human Retinal Pigment Epithelial Cells Through Nrf2-Mediated Activation of Heme Oxygenase-1,” was authored by Park C, Noh JS, Jung Y, Leem S-H, Hyun JW, Chang Y-C, Kwon TK, Kim G-Y, Lee H, and Choi YH, and appeared in Volume 13 of the journal in 2022.

The decision to retract the paper was triggered by concerns raised after publication regarding the authenticity of images used in the study’s figures. Specifically, Figure 3E from the retracted article was identified as having been previously published in a different scientific paper. This prior publication was authored by Kang J. S., Choi I. W., Han M. H., and colleagues, and appeared in BMC Complementary and Alternative Medicine in 2015.

Upon discovery of the duplicated image, Frontiers initiated an investigation in accordance with its established policies for handling research integrity concerns. The authors of the original 2022 article were given the opportunity to provide an explanation for the presence of the previously published figure. However, the authors failed to provide a satisfactory explanation during the course of the investigation. As a result, the journal concluded that the reliability of the data and the conclusions drawn in the article could not be maintained, leading to the formal retraction of the work.

The retraction notice was approved by the Chief Executive Editor of Frontiers. It is noted in the official documentation that the authors of the original study do not agree with the decision to retract their article. Despite this disagreement, the journal proceeded with the retraction based on the findings of the integrity investigation. The notice also acknowledges the role of the scientific community in identifying the issue, specifically thanking a user on the platform PubPeer for bringing the published article to the journal’s attention.

The retraction notice was published in Volume 17 of Frontiers in Pharmacology in 2026, under the section of Experimental Pharmacology and Drug Discovery. The notice was received and accepted on 23 October 2026, and published on 11 November 2026. The copyright for the retraction notice is held by the Frontiers Editorial Office, and the article is distributed under the terms of the Creative Commons Attribution License. This license permits the use, distribution, and reproduction of the retraction notice in other forums, provided that the original authors and copyright owners are credited and the original publication is cited.

Subject of Research: Retraction of a 2022 pharmacology study due to image integrity violations

Article Title: Retraction: Fisetin attenuated oxidative stress-induced cellular damage in ARPE-19 human retinal pigment epithelial cells through Nrf2-mediated activation of heme oxygenase-1

Article References: Frontiers Editorial Office (2026). Retraction: Fisetin attenuated oxidative stress-induced cellular damage in ARPE-19 human retinal pigment epithelial cells through Nrf2-mediated activation of heme oxygenase-1. Frontiers in Pharmacology, 17, Article 2038854. https://doi.org/10.3389/fphar.2026.2038854

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.2038854

Keywords: retraction, fisetin, ARPE-19 cells, oxidative stress, Nrf2 pathway, heme oxygenase-1, research integrity, image duplication, Frontiers in Pharmacology, retinal pigment epithelium, scientific misconduct, PubPeer, cellular damage, drug discovery, experimental pharmacology, data reliability, editorial decision, 2022 study, 2026 retraction, BMC Complementary and Alternative Medicine

News Source: Louis Brooks. (November 12, 2026). Frontiers retracts 2022 fisetin study over image integrity concerns. Scienmag.

Tags: 2022 study2026 retractionARPE-19 cellsBMC Complementary and Alternative Medicinecellular damagedata reliabilitydrug discoveryeditorial decisionexperimental pharmacologyfisetinFrontiers in Pharmacologyheme oxygenase 1image duplicationNRF2 pathwayoxidative stressPubPeerResearch Integrityretinal pigment epitheliumRetractionscientific misconduct
Share12Tweet7Share2ShareShareShare1

Related Posts

Staged Surgical Protocol Reconstructs Adolescent Mandible Following Ossifying Fibroma Resection

Staged Surgical Protocol Reconstructs Adolescent Mandible Following Ossifying Fibroma Resection

November 17, 2026
Comorbidities Associated With Lower RSV Humoral and Cellular Immunity in Older Adults

Comorbidities Associated With Lower RSV Humoral and Cellular Immunity in Older Adults

November 17, 2026

Visual Distraction Reduces Quantitative Light Touch Sensitivity in Healthy Adult Hand Testing

November 17, 2026

Herbal Iridoid Extract Relieves Fatty Liver Hemorrhagic Syndrome in Laying Hens

November 17, 2026

POPULAR NEWS

  • Staged Surgical Protocol Reconstructs Adolescent Mandible Following Ossifying Fibroma Resection

    Staged Surgical Protocol Reconstructs Adolescent Mandible Following Ossifying Fibroma Resection

    29 shares
    Share 12 Tweet 7
  • Microglia Study Identifies FKBP5 as a Regulator of Alzheimer’s Inflammation

    29 shares
    Share 12 Tweet 7
  • Holmium Substitution Improves SmFeO3 Supercapacitor Electrochemical Performance in KI/KOH Electrolyte

    29 shares
    Share 12 Tweet 7
  • Comorbidities Associated With Lower RSV Humoral and Cellular Immunity in Older Adults

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Staged Surgical Protocol Reconstructs Adolescent Mandible Following Ossifying Fibroma Resection

Microglia Study Identifies FKBP5 as a Regulator of Alzheimer’s Inflammation

Holmium Substitution Improves SmFeO3 Supercapacitor Electrochemical Performance in KI/KOH Electrolyte

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.